{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T04:25:52Z","timestamp":1792211152015,"version":"4.4.0"},"reference-count":13,"publisher":"SAGE Publications","issue":"7","license":[{"start":{"date-parts":[[2023,7,4]],"date-time":"2023-07-04T00:00:00Z","timestamp":1688428800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Enfortumab vedotin is an antibody drug conjugate approved for management of pretreated locally advanced or metastatic urothelial carcinoma, which is associated with a rare risk of drug extravasation and soft tissue reactions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case Report<\/jats:title>\n                    <jats:p>We report two cases of EV extravasation with subsequent development of bullae and cellulitis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Management and Outcome<\/jats:title>\n                    <jats:p>They were both treated for cellulitis and had conservative management without surgical intervention and were able to resume treatment with Enfortumab vedotin without subsequent adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>We propose that EV acts as a vesicant upon extravasation, highlight measures to prevent extravasation events, and encourage appropriate measures when dealing such as attempt of aspiration, removal of catheter, application of compresses, and thorough documentation with photographic evidence.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552231185505","type":"journal-article","created":{"date-parts":[[2023,7,4]],"date-time":"2023-07-04T03:12:42Z","timestamp":1688440362000},"page":"1789-1792","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":14,"title":["Drug extravasation with Enfortumab vedotin"],"prefix":"10.1177","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-6432-5635","authenticated-orcid":false,"given":"Christopher Ryan","family":"Grant","sequence":"first","affiliation":[{"name":"Department of Medicine, University of California Irvine Medical Center, Orange, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9609-3226","authenticated-orcid":false,"given":"Dimitri","family":"de Kouchkovsky","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of California \u2013 San Diego, La Jolla, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arash Rezazadeh","family":"Kalebasty","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, University of California Irvine Medical Center, Orange, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2485-6201","authenticated-orcid":false,"given":"Nataliya","family":"Mar","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, University of California Irvine Medical Center, Orange, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2023,7,4]]},"reference":[{"key":"bibr1-10781552231185505","unstructured":"Fda, Cder. HIGHLIGHTS OF PRESCRIBING INFORMATION. [cited 2023 Jan 11], www.fda.gov\/medwatch."},{"key":"bibr2-10781552231185505","unstructured":"Definition of extravasation - NCI Dictionary of Cancer Terms - NCI. [cited 2023 Jan 11], https:\/\/www.cancer.gov\/publications\/dictionaries\/cancer-terms\/def\/extravasation."},{"key":"bibr3-10781552231185505","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154"},{"key":"bibr4-10781552231185505","doi-asserted-by":"publisher","DOI":"10.5306\/wjco.v7.i1.87"},{"key":"bibr5-10781552231185505","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejon.2008.07.003"},{"key":"bibr6-10781552231185505","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.2016.020198"},{"key":"bibr7-10781552231185505","unstructured":"Genentech, Inc. HIGHLIGHTS OF PRESCRIBING INFORMATION. [cited 2023 Jan 12], www.fda.gov\/medwatch."},{"key":"bibr8-10781552231185505","doi-asserted-by":"publisher","DOI":"10.1177\/1758834013510546"},{"key":"bibr9-10781552231185505","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds294"},{"key":"bibr10-10781552231185505","doi-asserted-by":"publisher","DOI":"10.1177\/1078155220950005"},{"key":"bibr11-10781552231185505","doi-asserted-by":"publisher","DOI":"10.1097\/01.NAJ.0000282299.03441.c7"},{"key":"bibr12-10781552231185505","unstructured":"Management of Chemotherapy Extravasations. [cited 2023 Jan 1], https:\/\/www.uspharmacist.com\/article\/management-of-chemotherapy-extravasations."},{"key":"bibr13-10781552231185505","doi-asserted-by":"publisher","DOI":"10.1177\/106002808301701002"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552231185505","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552231185505","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552231185505","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:28:43Z","timestamp":1777688923000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552231185505"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,4]]},"references-count":13,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["10.1177\/10781552231185505"],"URL":"https:\/\/doi.org\/10.1177\/10781552231185505","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,4]]}}}